Pharmalgen®治疗蜜蜂和黄蜂的毒液过敏的临床和成本效益-医学文献翻译(中英对照).docVIP

The clinical and cost-effectiveness of Pharmalgen? for the treatment of bee and wasp venom allergy 1 TITLE OF PROJECT The clinical and cost effectiveness of Pharmalgen? for the treatment of bee and wasp venom allergy 2 TAR TEAM Liverpool Reviews and Implementation Group LRiG, University of Liverpool Correspondence to: Rumona Dickson, Ms Director, LRiG University of Liverpool Room 2.12 Whelan Building The Quadrangle Brownlow Hill Liverpool L69 3GB Tel: +44 0 151 794 5682 Fax: +44 0151 794 5585 Email: R.Dickson@ For details of expertise within the TAR team, see section 73 PLAIN ENGLISH SUMMARY Allergic reactions to bee and wasp venom may occur in venom-sensitive patients immediately following a sting, and can vary in severity, with initially mild symptoms sometimes progressing to critical conditions within seconds. The most severe systemic allergic reactions generalised reactions are known as anaphylaxis, a reaction characterised by abnormally low blood pressure, fainting or collapse, and in extreme reactions these symptoms can cause deathEach year in the UK there are between two and nine deaths from anaphylaxis caused by bee and wasp venom. The immediate treatment for severe allergic reactions to bee and wasp venom consists of emergency treatment with drugs to decrease the patient’s response to the venom and support breathing, if requiredTo avoid further reactions, the use of sensitisation to bee and wasp venom, through a process known as venom immunotherapy VIT, has been investigated. Venom immunotherapy consists of subcutaneous injections of increasing amounts of venom into patients with a history of anaphylaxis to bee and wasp venom. Pharmalgen? has had UK marketing authorisation for the diagnosis and treatment using VIT of allergy to bee venom using Pharmalgen? Bee Venom and wasp venom using Pharmalgen? Wasp Venom since March 1995, and it is used by more than 40 centres across the UK. This review aims to assess whether using Pharmalgen? in VIT